@drmirallas
Medical Oncologist MD Clinical Fellow @mdanderson.bsky.social Drug Development/Phase I Department 18-25' Thoracic Tumors Unit @VHIO.bsky.social Vocal Junta Govern #COMB Bcn '21-'25 Asesor y prof @SalutUIC since '19 #PhaseI #oncology #research #academy
🚀 just published @sitcancer.bsky.social #JITC
👥 34,973 pts
♻️ 47 #RCT
💉 PD-1 the earlier the better
HR=0.74
📌 #PFS2 great correlation to #OS
R² 0.74 #PFS2 vs 0.39 #PFS
Led by Dr. Jimenez-Labaig
@oncoalert.bsky.social @brunolarvol.bsky.social @vhio.bsky.social
👇🏽
jitc.bmj.com/content/jitc/1…
Moltes felicitats!!
#NIH did this. We fund medical research to help burn patients and benefit them and all Americans.
💥 Practice changing #SCLC ❗
📌 DeLLphi-304
Tarlatamab vs ChT 2L ED SCLC
✅ mOS 13.6 vs 8.3m
✅ mPFS 5.3 vs 4.3m
✅ ORR 35 vs 20%
☣️ =>G3 54 vs 80%
⚠️ Watch #CRS 56% and #ICAN for Tarla
🧠 45% brain M1
@oncoalert.bsky.social
@ascocancer.bsky.social
@myesmo.bsky.social
#OncoAlertAF
✍🏽 June 2👇🏽
#ASCO25
🔥 MATTERNHORN: adding #Durvalumab to FLOT GEJ/GC ADK resectable
🗣️ Dr. Janjigian
✅ DFS 67 vs 57% at 24m HR 0.71
✅ mOS 76 vs 70% at 24m
✅ pCR 19 vs 7%
90% PD-L1+
#OncoNexion25
@oncoalert.bsky.social
@ascocancer.bsky.social @vhio.bsky.social
@myesmo.bsky.social
#ASCO25
Drug development track 🔥
IZA-BREN/BL-B01D1
💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths
✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!
#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social
#ASCO2025
🔥 Drug development track
🕑 2:45pm
📉 Exciting science to be presented❗
New drugs into #trials
💉 Biespecific+/- ADC
💥 ADC+ IO
🎯 #KRASG12D
🧬 New small mol #KIF18A
🩸⚒️ More #ctDNA and new #IA
@oncoalert.bsky.social
@myesmo.bsky.social
👇🏽 My TOP 10 for #drugdevelopment
🤩 Exciting news !!
Great work led by Dr. Galip and Sütcüoglu #Turkey
📌 Impressive results of #PROMISE outside Spain
✅ Better mortality prediction over #GRm and #CTI
⬆️Risk OR 3.32 vs 2.85 vs 1.83
⬇️Risk OR 0.22 vs 0.35 vs 0.73
💥AUC promise 0.868!!
🙌🏽 Combined with CTI: AUC 0.884
Find more👇🏽
Ready to start the EACR Conference_Persister Cells: from Bacteria to Cancer in Lyon!!!
@helloeacr.bsky.social @vhio.bsky.social
📢 It has been a learning experience over the past 3 days at #ESMOTAT25 to listen to experts in the field of #phaseI #drugdevelopment
🗣️ The talks were truly insightful
✅ New and improved drugs 🎯
📊 Innovative trial designs
@myesmo.bsky.social
@viveksubbiah.bsky.social
@oncoalert.bsky.social
Thanks #ESMOTAT25 & #ESMOYOC for the kind invitation to speak alongside #TeamManchester colleague Dr André Freitas - AI/ML 👨💻 expert @cruk-mi.bsky.social.
We discussed tips & tricks + pitfalls of using (generative) AI 🤖 for paper and grant writing.
@uom-dcs.bsky.social
@mcrcnews.bsky.social
#ESMOTAT25
🔥 Starting the day with #AI tools and it's application to #science and writing grants/papers
✅ Helping in style and format
✅ Prompts very important
❌ Plagiarism, repetition, bad for searching
Great talks by @drjonlim.bsky.social Dr Freitas
#YOC @myesmo.bsky.social @vhio.bsky.social
¿A punto de elegir tu especialidad #MIR? ¡Este evento es para ti ‼️
💬 Te contamos todo sobre #OncologíaMédica en @vallhebroncampus.bsky.social: nuestro programa, oportunidades y resolvemos tus dudas en solo 30 min.
📅 21/02 | ⏰ 11:00 h ℹ️ https://linke.to/PostMir25
#ResisOncoVH
🚀 Encorafenib&Cetuximab + mFOLFOX6 vs #CT choice
#BREAKWATER P3 for #CRC with BRAF V600E mut
💊💊+💉
👉🏽 ORR 60.9%
👉🏽 mOS NE
☣️ G3/4 74%
💉
👉🏽 ORR 40%
👉🏽 mOS 14.6m
☣️ G3/4 61%
✅ Met ORR #primary endpoint
❌ OS just yet
@natmedicine.bsky.social
@vhio.bsky.social
www.nature.com/articles/s41...
📢 Less than 6 hrs until @ASCO #abstractsubmission ❗
⚠️ Deadline ⚠️
🕕 6am Europe #Spain time
🕛 11:59pm EST
#ASCO25
❤️🔥Burning midnight here in Europe 🇪🇺
🏃🏽♂️ #FinishTheJob
🙌🏽 Hope to see you all in Chicago
@vhio.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social @vallhebroncampus.bsky.social
